stoxline Quote Chart Rank Option Currency Glossary
  
23andMe Holding Co. (ME)
0.6063  0 (0%)    04-01 16:00
Open: 0.748
High: 0.748
Volume: 29,751,445
  
Pre. Close: 0.6063
Low: 0.6063
Market Cap: 13(M)
Technical analysis
2025-05-16 12:48:43 PM
Short term     
Mid term     
Targets 6-month :  1.54 1-year :  1.92
Resists First :  1.32 Second :  1.64
Pivot price 1.25
Supports First :  0.8 Second :  0.66
MAs MA(5) :  1.01 MA(20) :  1.25
MA(100) :  2.2 MA(250) :  5.02
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  7.5 D(3) :  10.9
RSI RSI(14): 34.1
52-week High :  12.76 Low :  0.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ME ] has closed below the lower bollinger band by 0.8%. Bollinger Bands are 30.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.01 - 1.02 1.02 - 1.02
Low: 0.88 - 0.89 0.89 - 0.9
Close: 0.89 - 0.91 0.91 - 0.92
Company Description

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Headline News

Mon, 31 Mar 2025
What Happens to Your Personal Data When a Company Folds? - Investopedia

Wed, 26 Mar 2025
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law - Yahoo Finance

Mon, 24 Mar 2025
Anne Wojcicki Had a Fully Financed Plan to Take 23andMe Private. Then It Fell Apart. - MedCity News

Mon, 24 Mar 2025
23andMe is filing for bankruptcy. Here's what it means for your genetic data - NPR

Mon, 24 Mar 2025
23andMe's journey from DNA testing pioneer to bankruptcy - Reuters

Mon, 24 Mar 2025
23andMe files for bankruptcy. Here’s what may be next for the DNA-kit company. - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 20 (M)
Shares Float 16 (M)
Held by Insiders 17.2 (%)
Held by Institutions 26 (%)
Shares Short 1,790 (K)
Shares Short P.Month 1,390 (K)
Stock Financials
EPS -17.39
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.34
Profit Margin -187 %
Operating Margin -41.9 %
Return on Assets (ttm) -33.2 %
Return on Equity (ttm) -193.8 %
Qtrly Rev. Growth 34.7 %
Gross Profit (p.s.) 5.61
Sales Per Share 10.58
EBITDA (p.s.) -11.14
Qtrly Earnings Growth 0 %
Operating Cash Flow -155 (M)
Levered Free Cash Flow -33 (M)
Stock Valuations
PE Ratio -0.05
PEG Ratio 0
Price to Book value 0.36
Price to Sales 0.08
Price to Cash Flow -0.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android